issued
on 24 Sep 2024
Last Applicant/ Owned by
131, Gasandigital 1-ro, Geumcheon-gu,
Seoul,
KR
08506
Serial Number
98018569 filed on 30th May 2023
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Research and development of DNA chips; structural and functional analysis of genomes; scientific laboratory services; advisory services relating to scientific research; providing information relating to scientific research; advisory services relating to biotechnology; research relating to biotechnology; biological research services; biochemical analysis; biochemistry research services; scientific Read More
Research and development of DNA chips; structural and functional analysis of genomes; scientific laboratory services; advisory services relating to scientific research; providing information relating to scientific research; advisory services relating to biotechnology; research relating to biotechnology; biological research services; biochemical analysis; biochemistry research services; scientific research in the field of gene analysis; customized genetic scientific research; pharmaceutical research; medical research; clinical research in the field of oncology, cardiovascular disease neurology, immunology, and genomics; blood testing for scientific research purposes; consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of biomedicine; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; chemical research; research for medical products, namely, medical research; scientific research in the nature of conducting clinical trials for others in the field of oncology, cardiovascular disease, neurology, immunology, and genomics; biotechnology research; biochemical research; providing information of scientific research.
N/A
N/A
Biotechnological preparations, namely, reagents for medical purposes; pharmaceutical preparations for activating cellular function for the treatment of cancer, infectious disease, autoimmune disease, cardiovascular disease, and allergy; chemical preparations for pharmaceutical purposes, namely, for cancer, infectious disease, autoimmune disease, cardiovascular disease, and allergy; chemical preparations for medical purposes, namely, for cancer, infectious disease, autoimmune disease, cardiovascular disease, and allergy; siccatives being drying agents for medical purposes; reagents for in-vitro laboratory use for medical purposes; cleansing solutions for medical use; reagents for medical use; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, infectious disease, autoimmune disease, cardiovascular disease, and allergy; enzymes for medical purposes; enzyme preparations for medical purposes; nucleic acid sequences for medical and veterinary purposes; chemical preparations for use in DNA analysis for medical purposes, namely, for cancer, infectious disease, autoimmune disease, cardiovascular disease, and allergy; in vitro diagnostic preparations for medical purposes; diagnostic test reagents for medical or veterinary purposes; biological and chemical reagents for medical or veterinary purposes; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing.
N/A
N/A
No 98018569
No Service Mark
No TUS230038
No
No
No
No
No
No
No
No
26.01.29 -
Helixes
Status Date | Action Taken |
---|---|
24th Sep 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
30th Jul 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
30th Jul 2024 | PUBLISHED FOR OPPOSITION |
10th Jul 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
12th Jun 2024 | EXAMINERS AMENDMENT E-MAILED |
12th Jun 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
12th Jun 2024 | EXAMINER'S AMENDMENT ENTERED |
12th Jun 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
12th Jun 2024 | EXAMINERS AMENDMENT -WRITTEN |
27th May 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |